Here s why Sage Therapeutics fell 18% on Tuesday morning invezz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from invezz.com Daily Mail and Mail on Sunday newspapers.
Print
“Communication in History: The Key to Understanding” was the topic for students in this year’s California National History Day competition, which recently announced its winners.
Students competed virtually to explore the theme, doing original research on topics from spies and comic books to the Pony Express and Hedy Lamarr. They used posters, videos, websites, performances, exhibits and essay papers to illustrate their projects. In developing their ideas, the students learn and improve critical thinking, research and reading skills, and problem-solving and teamwork.
National History Day
is an education nonprofit based in College Park, Md. The competitions draw more than a half-million middle and high school students each year from across the nation. Students taking honors from San Diego County are:
Operator
Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies First Quarter 2021 Financial Results Conference Call. As a reminder, today s conference call is being recorded.
I d now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.
Juan Sanchez
Vice President of Corporate Communications and Investor Relations
Good morning and thank you all for joining us for today s conference call. Our earnings press release provides a corporate update and details of the company s financial results for the first quarter ended March 31, 2021. This press release crossed the wire a short time ago and is available on our website at intracellulartherapies.com.
Businesswire This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Barry Greene took over as Sage s CEO after it cut the entire sales force behind its first drug.
Its second drug, zuranolone, must compete with cheap depression drugs already on the market.
The zuranolone launch could also affect Biogen s business, thanks to a $3.1 billion partnership.
When Barry Greene took over as CEO of Sage Therapeutics in December, he inherited a company that was hoping to turn the page after a bad chapter.
The biotech has had a rocky year. The company struggled to sell its first drug, and the second had failed to help patients with depression in a late-stage clinical trial. In April, former CEO Jeff Jonas cut 53% of the company s entire workforce to mitigate the financial drain.
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
VistaGen Therapeutics (NASDAQ:VTGN) were soaring 22.1% as of 11:27 a.m. EST on Thursday. The big jump came after
Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen s shares at the market close on Wednesday.
So what
Wall Street analysts aren t always right with their recommendations and price targets. But it s a good idea to at least understand why they re bullish about a stock.